In the future, these findings will inspire novel therapeutics strategies for the use of PARP3-specific inhibitors combined with microtubules targeting agents to overcome tumor hypoxia as a barrier to effective cancer treatment in glioblastoma. Here, PARP3 is linked to glioblastoma.